

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.



Jacobson Pharma Corporation Limited

雅各臣科研製藥有限公司

(Incorporated under the laws of the Cayman Islands with limited liability)

Stock Code : 2633

SUPPLEMENTAL ANNOUNCEMENT IN RELATION TO THE ANNUAL REPORT FOR THE YEAR ENDED 31 MARCH 2018

Reference is made to the annual report of Jacobson Pharma Corporation Limited (the “**Company**”) for the year ended 31 March 2018 published on 26 July 2018 (the “**2018 Annual Report**”). Unless otherwise defined, capitalised terms used herein shall have same meanings as those defined in the 2018 Annual Report.

Further to the information as set out in the 2018 Annual Report, the Company would like to provide additional information on the net proceeds of HK\$490,352,000 raised from the issuance of convertible notes (“**Net Proceeds**”) under the sub-section entitled “**USE OF PROCEEDS**” under the section headed “**MANAGEMENT DISCUSSION AND ANALYSIS**” on page 24 of the 2018 Annual Report as follows:

- The details of the actual use of Net Proceeds during the year ended 31 March 2018 and the detailed breakdown of the projected application of the unutilised Net Proceeds as at 31 March 2018 are as follows:

	Actual use of Net Proceeds during the year ended 31 March 2018 HK\$'000	Projected application of the unutilised Net Proceeds HK\$'000
Funding potential mergers and acquisitions as well as forming strategic alliances in the Asia Pacific region	117,757 ^(note i)	293,595 ^(note iii)
Supporting in-licensing and direct investment on technologically-oriented bio-pharmaceutical projects	7,828 ^(note ii)	71,172
	125,585	364,767

Notes:

- (i) On 20 December 2017, a wholly-owned subsidiary of the Company, namely Joyful Ascent Limited (“**Subscriber**”), entered into the capital increase agreement (“**Capital Increase Agreement**”) with, among others, Shanghai Henlius Biotech Inc.* (上海復宏漢霖生物技術股份有限公司) (“**Shanghai Henlius**”) (a joint stock company incorporated in the People’s Republic of China with limited liability and its Application Proof (as defined under the Listing Rules) is published on the website of the Stock Exchange on 5 July 2019), for a consideration of RMB99,388,544 (approximately HK\$117.8 million). Please refer to the Company’s announcements dated 20 December 2017 and 30 January 2018 for further details.
 - (ii) On 20 December 2017, a wholly-owned subsidiary of the Company, namely Jacobson Medical (Hong Kong) Limited (“**Jacobson Medical**”), entered into a licensing framework agreement (“**Licensing Framework Agreement**”) with Shanghai Henlius, in relation to the licensing and commercialisation of a biosimilar product of Trastuzumab (“**Product**”) in Hong Kong and Macau. Jacobson Medical had made an initial good faith payment of USD1,000,000 (approximately HK\$7.8 million) to Shanghai Henlius upon entering into the Licensing Framework Agreement. Jacobson Medical will also have a right of first negotiation towards entering into a definitive agreement to commercialise the Product in certain emerging markets within Asean domains subject to the terms of the Licensing Framework Agreement. Please refer to the Company’s announcement dated 20 December 2017 for further details.
 - (iii) The potential mergers and acquisitions are in relation to proprietary medicines business, pharmaceutical projects as well as forming strategic alliances in the Asia Pacific region.
2. The Company expects that the unutilised Net Proceeds as at 31 March 2018 will be used up on or before 31 March 2020.
 3. The Net Proceeds were used and are proposed to be used in accordance with the intended uses as previously disclosed in the Company’s announcements dated 6 September 2017 and 3 October 2017.

Save as disclosed above, all other information in the 2018 Annual Report shall remain unchanged and the Board confirmed that the above additional information does not affect other information contained in the 2018 Annual Report.

By Order of the Board
Jacobson Pharma Corporation Limited
Yim Chun Leung
Executive Director and Company Secretary

Hong Kong, 15 July 2019

As at the date of this announcement, the Board comprises Mr. Sum Kwong Yip, Derek (also as Chairman and Chief Executive Officer), Mr. Yim Chun Leung and Ms. Pun Yue Wai as executive Directors, Professor Lam Sing Kwong, Simon as non-executive Director, and Dr. Lam Kwing Tong, Alan, Mr. Young Chun Man, Kenneth and Professor Wong Chi Kei, Ian as independent non-executive Directors.

* *For identification purposes only*